Tirzepatide and Gut Microbiome: A Narrative Review of Current Evidence and Future Implications
Preprint
- 17 September 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Tirzepatide has recently been approved for use with type 2 diabetes and obesity due to its effectiveness with both and being the first dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Increasing focus has shifted toward tirzepatide’s possible relationships with the gut microbiome, which plays an important role in metabolic, bile acid, and inflammation regulation, in addition to its many established benefits in glucose control and weight loss. Gut microbial composition changes are known to lead to obesity, insulin resistance, and related comorbidities, which is why this area is so important. Tirzepatide has been shown to increase the absent flora diversity of the gut in addition to the increased growth of beneficial Akkermansia and Bacteroides, and the alteration of bile acid metabolism toward microbial antagonists of the farnesoid X receptor. Lubricated insulin resistance and systemic inflammation, coupled with the imbalance of gut flora resulting from a diet high in fats, have been linked to these changes. Preliminary studies support the idea that tirzepatide’s dual mechanism has a more profound influence over the microbial ecology and metabolic pathways than the effects of other GLP-1 receptor agonists and DPP-4 inhibitors. Overall, the safety data regarding tirzepatide appear to be in line with other therapies based on incretins, with gastrointestinal side effects being the most common adverse event. Its effects on metabolism and the microbiome, however, are broader than glucose and weight management. Early data suggest potential benefits in NAFLD, inflammatory bowel disease, cardiovascular dysfunction, and even some neurodegenerative diseases. Tirzepatide embodies a promising advance in the intersection of incretin biology and gut microbiome regulation for precision medicine in metabolic disease. The focus on the microbiome in future studies will be important for substantiating and elucidating the mechanisms of these observations, enhancing patient stratification for precision medicine approaches.Keywords
All Related Versions
This publication has 21 references indexed in Scilit:
- Efficacy of tirzepatide for weight loss and it’s comparative effectiveness to weight loss surgery in inflammatory bowel diseaseIndian Journal of Gastroenterology, 2025
- The role of gut microbiota in Tirzepatide-mediated alleviation of high-fat diet-induced obesityEuropean Journal of Pharmacology, 2025
- Gut microbiota mediates semaglutide attenuation of diabetes-associated cognitive declineNeurotherapeutics, 2025
- Dual GIP and GLP-1 receptor agonist tirzepatide alleviates hepatic steatosis and modulates gut microbiota and bile acid metabolism in diabetic miceInternational Immunopharmacology, 2025
- Gut microbiota in human metabolic health and diseaseNature Reviews Microbiology, 2020
- Advances in oral peptide therapeuticsNature Reviews Drug Discovery, 2019
- Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasisEBioMedicine, 2019
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of conceptMolecular Metabolism, 2018
- Identification of therapeutic effect of glucagon‐like peptide 1 in the treatment of STZ‐induced diabetes mellitus in rats by restoring the balance of intestinal floraJournal of Cellular Biochemistry, 2018
- Decreased glucagon-like peptide-1 correlates with abdominal pain in patients with constipation-predominant irritable bowel syndromeClinics and Research in Hepatology and Gastroenterology, 2017